Emami Limited Revenue Flat at ₹3,780 Cr; Declares Total ₹10 Dividend Amid D2C Pivot

Synopsis:- Emami Limited reported a 0.8 percent decline in consolidated revenue to Rs.3,780 crore for FY26, weighed down by a 16 percent contraction in the summer portfolio and a 5 percent international revenue decline in Q4 due to the West Asia conflict  but the non-summer domestic business grew 5 percent for the year and 11 percent in Q4, EBITDA margins expanded 130 basis points to 69.9 percent gross, and the company ended the year debt-free with Rs.883 crore in net cash.

Shares of one of India’s leading FMCG companies came into focus after its Board of Directors met on May 21, 2026 to approve Q4 and full-year FY26 audited results. The results tell a tale of two portfolios: a summer-dependent business that was structurally impaired by an unfavourable season, and an underlying core franchise that held its ground with credible consistency.

With a market capitalization of Rs. 18,197.69  crore, the shares of Emami Limited were last recorded at Rs. 417.6 per share, down 2.61 percent from its previous close of Rs. 428.8. The stock trades at a P/E of 23.44.

Consolidated revenue from operations declined 0.8 percent to Rs. 3,779.5 crore from Rs. 3,809.2 crore in FY25. EBITDA fell 6 percent to Rs. 963.6 crore, with the EBITDA margin contracting 140 basis points to 25.5 percent  the erosion coming primarily from a 140 basis point increase in advertising and promotional spend (to 19.6 percent of revenues) and a 100 basis point increase in staff costs, even as gross margins expanded 130 basis points to 69.9 percent.

PAT declined 3.4 percent to Rs. 775.3 crore from Rs. 802.7 crore in FY25, with an exceptional charge of Rs. 10.1 crore (related to the Axiom Ayurveda stake transition) modestly impacting the reported bottom line.

Q4 FY26 was the weak quarter that dragged the full year down. Consolidated revenues fell 3.9 percent year-on-year to Rs. 925.1 crore, EBITDA declined 14.9 percent to Rs.186.7 crore, and PAT fell 11.7 percent to Rs. 143.2 crore. Despite that, gross margins for the quarter expanded 250 basis points, a direct result of input cost management and pricing discipline even as volumes fell.

Emami’s summer portfolio  primarily Navratna and Dermicool  contracted 15 percent for the full year and 21 percent in Q4, accounting for the entirety of the company’s revenue underperformance. Excluding this segment, the domestic business delivered 5 percent revenue growth for FY26 and 11 percent in Q4. In Q4, Pain Management grew 11 percent, Kesh King grew 14 percent,

Healthcare was up 7 percent, 7 Oils in One grew 34 percent, and The Man Company and Brillare together grew 34 percent, a growth profile that is structurally healthy. The summer portfolio’s contraction reflects an adverse monsoon calendar and seasonal conditions rather than brand or distribution failure, and management expects normalisation from Q1 FY27 as early summer trends improve.

Volume data reinforces this: domestic volume growth excluding the summer portfolio was 7 percent in Q4, indicating that pricing was not carried as a crutch. For the full year, domestic ex-summer volumes grew in positive territory while the summer portfolio’s volume decline of mid-teens was driven by ambient temperatures rather than market share loss.

Emami’s international business, contributing approximately 18 percent of consolidated revenues, was caught in the crossfire. For January and February 2026, international revenues grew 16 percent year-on-year  suggesting strong underlying demand. In March, however, the Strait of Hormuz disruption affected shipping routes and raised freight costs materially across the West Asia corridor, pulling Q4 international growth down to negative 5 percent. For the full year, international revenues grew 3 percent, with SAARC and South East Asia remaining steady contributors.

The geopolitical timing matters for interpretation: Emami’s international weakness in Q4 was entirely calendar-driven, and to the extent the US–Iran diplomatic channel advances, the freight and supply chain normalisation could restore growth from Q1 FY27 itself.

Emami ended FY26 with net cash of Rs. 883 crore  combining Rs.176.8 crore in cash and equivalents, Rs. 233.1 crore in other bank balances, Rs. 471.9 crore in current investments, against current borrowings of Rs.122.4 crore. The balance sheet is debt-free in operational terms and provides the capital base for the acquisitions announced for FY27. The Board declared two interim dividends during FY26  Rs.4 per share in November 2025 and Rs.6 per share in February 2026  totalling Rs.10 per share and Rs. 436.5 crore in payout, representing 51 percent of adjusted profits and 56 percent of reported PAT.

The most forward-looking disclosures concern Q1 FY27. Emami has increased its stake in Axiom Ayurveda  the company behind the AloFrut aloe vera drink  converting it into a subsidiary effective April 1, 2026, with acquisition of the remaining stake expected by June 2026. Separately, the company is acquiring a majority stake in IncNut Digital, which owns Vedix (personalised Ayurvedic hair care) and SkinKraft (personalised skincare).

Both moves are directed at the same strategic logic: building a portfolio of digital-first, new-age FMCG brands that skew younger and are growing materially faster than the legacy business. D2C brands already contribute 9 percent of domestic business, up from zero in FY20, with a five-year CAGR of 83 percent. The IncNut addition is designed to accelerate this further.

The risk is integration: Emami has made multiple acquisitions over the years  Kesh King, Creme 21, Dermicool, The Man Company  with varying degrees of P&L contribution. Whether Axiom and IncNut can be scaled without disproportionate A&P spend will be the metric to track over the next two to three years.

Business Overview

Founded in 1974 and headquartered in Kolkata, Emami Limited is one of India’s leading FMCG companies. Its portfolio of over 550 products spans personal care and healthcare, with flagship brands including Navratna, BoroPlus, Zandu, Kesh King, and Dermicool. The company distributes through over 5.4 million retail outlets and is present in 70+ countries. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Emami Limited Revenue Flat at ₹3,780 Cr; Declares Total ₹10 Dividend Amid D2C Pivot appeared first on Trade Brains.